SABS

SAB Biotherapeutics

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 2

Sell signal 1

stock price surged significantly

consensus rating "Strong Buy"

EPS Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About SABS

Sab Biotherapeutics, Inc.

A clinical-stage biopharmaceutical company engages in advancing immunotherapies leveraging human polyclonal antibodies

Industry

Biological Technology

Established Date

11/12/2020

Listing Date

02/09/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.sabbiotherapeutics.com

Security Type

Common stock

Office address

2100 East 54th Street North, Sioux Falls, South Dakota 57104

Business

Introduction

SAB Biotherapeutics, Inc., was incorporated in Delaware on November 12, 2020. The company is a clinical-stage biopharmaceutical company that uses fully human polyclonal antibodies to advance a new class of immunotherapies. SAB has applied advanced genetic engineering and antibody science to develop a transchromosomal (Tc) Bovine herd that can produce fully human antibodies against specific diseases, including infectious diseases such as COVID - 19 and influenza, immune system diseases such as type 1 diabetes and organ transplantation, and cancer. SAB's multifunctional DiversitAb platform is suitable for a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, highly effective human polyclonal immunotherapy. SAB is currently advancing several clinical programs and working with the U.S. government and global pharmaceutical companies.

Company Financials

EPS

SABS has released its 2024 Q1 earnings. EPS was reported at -0.54, versus the expected -0.96, beating expectations. The chart below visualizes how SABS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

SABS has released its 2024 Q4 earnings report, with revenue of 114.70K, reflecting a YoY change of -62.40%, and net profit of -11.39M, showing a YoY change of 50.15%. The Sankey diagram below clearly presents SABS’s revenue sources and cost distribution.